http://hl7.org.nz/fhir/ig/cca/PlanDefinition/60071000210106
type: PlanDefinition
node role: treeRoot
id:
  v: 60071000210106
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition
    l: CcaPlanDefinition
text:
  status:
    v: extensions
  div:
    v: GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel Treatment Overview This regimen consists of two parts: cISplatin chemoradiation followed by cARBOplatin and PACLItaxel. Do not confuse with the chemotherapy-only regimen: GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only]. Part 1: cISplatin chemoradiation Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy. Part 2: cARBOplatin and PACLItaxel Commence within 3 weeks after completion of radiation therapy. Supportive Care Factors Factor Value Emetogenicity: High Growth factor support: Variable Hydration: Variable Hypersensitivity / Infusion related reaction risk: Variable References de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189 de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040 de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626 Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112 Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, …
contained: PlanDefinition
  meta:
    profile:
      v: http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition
      l: CcaPlanDefinition
  text:
    status:
      v: extensions
    div:
      v: Part 1: cISplatin chemoradiation (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel) Treatment Overview Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy. Cycle 1 - 28 days Cycle length: 28 Cycle details Cycle 1 - 28 days Medication Dose Route Days Max Duration olanzapine * 5 mg oral administration 1 to 4, 22 to 25 aprepitant 125 mg oral administration 1, 22 aprepitant 80 mg oral administration 2, 3, 23, 24 dexamethasone * 12 mg oral administration 1, 22 dexamethasone * 8 mg oral administration 2, 3, 4, 23, 24, 25 ondansetron 8 mg oral administration 1, 22 magnesium sulfate heptahydrate 10 mmol intravenous 1, 22 60 minutes cISplatin * 50 mg/m² intravenous 1, 22 60 minutes sodium chloride 0.9 % intravenous 1, 22 60 minutes ondansetron 8 mg oral administration 1, 22 cycliZINE 50 mg Three times daily oral administration 1 Full details Cycle 1 - 28 days Day: 1 Medication Dose Route Max duration Details olanzapine * 5 mg oral administration Instructions: ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment. aprepitant 125 mg oral administration Instructions: ONE hour prior to chemotherapy. dexamethasone * 12 mg oral administration Instructions: ONE hour prior to chemotherapy with food. ondansetron 8 mg oral administration Instructions: ONE hour prior to chemotherapy. magnesium sulfate heptahydrate 10 mmol intravenous 60 minutes Instructions: In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion. cISplatin * 50 mg/m² intravenous 60 minutes Instructions: In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin…
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
        l: sact-off-label
      value: Boolean
        v: true
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
        l: sact-is-supportive-care
      value: Boolean
        v: true
    status:
      v: active
    product: CodeableConcept
      text:
        v: olanzapine
    dosage:
      text:
        v: 5 mg by oral administration
      route:
        coding: http://snomed.info/id/386359008
      dose and rate:
        dose: Quantity
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
        l: sact-off-label
      value: Boolean
        v: false
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
        l: sact-is-supportive-care
      value: Boolean
        v: true
    status:
      v: active
    product: CodeableConcept
      text:
        v: aprepitant
    dosage:
      text:
        v: 125 mg by oral administration
      route:
        coding: http://snomed.info/id/386359008
      dose and rate:
        dose: Quantity
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
        l: sact-off-label
      value: Boolean
        v: false
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
        l: sact-is-supportive-care
      value: Boolean
        v: true
    status:
      v: active
    product: CodeableConcept
      text:
        v: aprepitant
    dosage:
      text:
        v: 80 mg by oral administration
      route:
        coding: http://snomed.info/id/386359008
      dose and rate:
        dose: Quantity
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
        l: sact-off-label
      value: Boolean
        v: true
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
        l: sact-is-supportive-care
      value: Boolean
        v: true
    status:
      v: active
    product: CodeableConcept
      text:
        v: dexamethasone
    dosage:
      text:
        v: 12 mg by oral administration
      route:
        coding: http://snomed.info/id/386359008
      dose and rate:
        dose: Quantity
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
        l: sact-off-label
      value: Boolean
        v: true
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
        l: sact-is-supportive-care
      value: Boolean
        v: true
    status:
      v: active
    product: CodeableConcept
      text:
        v: dexamethasone
    dosage:
      text:
        v: 8 mg by oral administration
      route:
        coding: http://snomed.info/id/386359008
      dose and rate:
        dose: Quantity
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
        l: sact-off-label
      value: Boolean
        v: false
    extension:
      url:
        v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
        l: sact-is-supportive-care
      value: Boolean
        v: true
    status:
      v: active
    product: CodeableConcept
      text:
        v: ondansetron
    dosage:
      text:
        v: 8 mg by oral administration
      route:
        coding: http://snomed.info/id/386359008
      dose and rate:
        dose: Quantity
  contained: ActivityDefinition
    meta:
      profile:
        v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
        l: CcaActivityDefinition
    product: CodeableConcept

v: 10757201000116108

v: olanzapine

http://snomed.info/id/386359008
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 386359008

v: oral administration

Quantity
value:
  v: 5
unit:
  v: mg
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 258684004

v: 10224481000116104

v: aprepitant

http://snomed.info/id/386359008
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 386359008

v: oral administration

Quantity
value:
  v: 125
unit:
  v: mg
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 258684004

v: 10224481000116104

v: aprepitant

http://snomed.info/id/386359008
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 386359008

v: oral administration

Quantity
value:
  v: 80
unit:
  v: mg
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 258684004

v: 10238921000116102

v: dexamethasone

http://snomed.info/id/386359008
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 386359008

v: oral administration

Quantity
value:
  v: 12
unit:
  v: mg
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 258684004

v: 10238921000116102

v: dexamethasone

http://snomed.info/id/386359008
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 386359008

v: oral administration

Quantity
value:
  v: 8
unit:
  v: mg
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 258684004

v: 10497011000116104

v: ondansetron

http://snomed.info/id/386359008
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 386359008

v: oral administration

Quantity
value:
  v: 8
unit:
  v: mg
system:
  v: http://snomed.info/sct
  l: sct
code:
  v: 258684004

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
  l: sact-off-label
value: Boolean
  v: false

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
  l: sact-is-supportive-care
value: Boolean
  v: true

v: active

CodeableConcept
coding:
  system:
    v: http://nzmt.org.nz
    l: nzmt.org.nz
  code:
    v: 20020231000116101
  display:
    v: magnesium sulfate heptahydrate
text:
  v: magnesium sulfate heptahydrate

text:
  v: 10 mmol over 60 minutes by intravenous
route:
  coding: http://snomed.info/id/386358000
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 386358000
  text:
    v: intravenous
dose and rate:
  dose: Quantity
    value:
      v: 10
    unit:
      v: mmol
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 258718000
  rate: Range
    high:
      value:
        v: 60
      unit:
        v: Min
      system:
        v: http://unitsofmeasure.org
        l: unitsofmeasure.org

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10182171000116105
    display:
      v: cISplatin
  text:
    v: cISplatin
dosage:
  text:
    v: 50 mg/m² over 60 minutes by intravenous
  route:
    coding: http://snomed.info/id/386358000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386358000
    text:
      v: intravenous
  dose and rate:
    dose: Quantity
      value:
        v: 50
      unit:
        v: mg/m²
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 404216004
    rate: Range

v: 60

v: Min

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: false
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10759231000116105
    display:
      v: sodium chloride
  text:
    v: sodium chloride
quantity:
  value:
    v: 1000
  unit:
    v: mL
  system:
    v: http://snomed.info/sct
    l: sct
  code:
    v: 258773002
dosage:
  text:
    v: 0.9 % over 60 minutes by intravenous
  route:
    coding: http://snomed.info/id/386358000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386358000
    text:
      v: intravenous
  dose and rate:
    dose: Quantity
      value:
        v: 0.9
      unit:
        v: %
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 118582008
    rate: Range

v: 60

v: Min

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: false
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10497011000116104
    display:
      v: ondansetron
  text:
    v: ondansetron
dosage:
  text:
    v: 8 mg by oral administration
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 8
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: false
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 44123411000116107
    display:
      v: cycliZINE
  text:
    v: cycliZINE
dosage:
  text:
    v: 50 mg Three times daily by oral administration
  timing:
    code:
      coding: http://snomed.info/id/229798009
      text:
        v: Three times daily
  as needed: Boolean
    v: true
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 50
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

v: 229798009

v: TID

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions
  l: sact-plan-instructions
value: Markdown
  v: Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer
  l: sact-disclaimer
value: Markdown
  v: The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/419219000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 419219000
    text:
      v: Emetogenicity
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/75540009
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 75540009
    text:
      v: High
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/281800008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 281800008
    text:
      v: Hydration
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/54261000210107
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 54261000210107
    text:
      v: Routine hydration recommended
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

system:
  v: CUSTOM
  l: CUSTOM

v: 0.0.5

v: GYN - cISplatin chemoradiation

v: Part 1: cISplatin chemoradiation (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel)

v: Gynaecological - cISplatin chemoradiation

coding:
  system:
    v: http://terminology.hl7.org/CodeSystem/plan-definition-type
    l: plan-definition-type
  code:
    v: clinical-protocol

v: active

v: 2022-10-13

v: New Zealand Medicines Formulary LP

v: A drug treatment regimen for Gynaecological - cISplatin chemoradiation

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/usage-context-type
    l: usage-context-type
  code:
    v: focus
value: CodeableConcept
  coding: http://snomed.info/id/310789003
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 310789003
  text:
    v: Gynaecological

v: All rights reserved.

name:
  v: New Zealand Medicines Formulary LP

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189
url:
  v: https://pubmed.ncbi.nlm.nih.gov/29449189
  l: https://pubmed.ncbi.nlm.nih.gov/29449189
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/29449189
    l: https://pubmed.ncbi.nlm.nih.gov/29449189

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040
url:
  v: https://pubmed.ncbi.nlm.nih.gov/27397040
  l: https://pubmed.ncbi.nlm.nih.gov/27397040
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/27397040
    l: https://pubmed.ncbi.nlm.nih.gov/27397040

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626
url:
  v: https://pubmed.ncbi.nlm.nih.gov/31345626
  l: https://pubmed.ncbi.nlm.nih.gov/31345626
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/31345626
    l: https://pubmed.ncbi.nlm.nih.gov/31345626

type:
  v: citation
display:
  v: Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112
url:
  v: https://pubmed.ncbi.nlm.nih.gov/25089112
  l: https://pubmed.ncbi.nlm.nih.gov/25089112
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/25089112
    l: https://pubmed.ncbi.nlm.nih.gov/25089112

type:
  v: citation
display:
  v: Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).

prefix:
  v: 1
description:
  v: Cycle 1 - 28 days
timing: Timing
  repeat:
    count:
      v: 1
    duration:
      v: 28
    duration unit:
      v: d
selection behavior:
  v: all
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 2
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 3
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 4
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 22
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake. Some centres may choose to omit pre-chemotherapy dose or advise patient to take the night before chemotherapy if patient has to drive to appointment.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 23
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 24
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 25
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily. This medicine may make you sleepy and make it dangerous to drive or operate machinery. Limit alcohol intake.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 22
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 2
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily in the morning.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 3
  definition: Canonical

url:
  v: instructions
  l: instructions
value: Markdown
  v: ONCE daily in the morning.

extension:
  url:
    v: day
    l: day
  value: Integer
    v: 23
extension:
  url:
    v: instructions
    l: instructions
  value: Markdown
    v: ONCE daily in the morning.
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
  l: sact-timing-of-days

extension:
  url:
    v: day
    l: day
  value: Integer
    v: 24
extension:
  url:
    v: instructions
    l: instructions
  value: Markdown
    v: ONCE daily in the morning.
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
  l: sact-timing-of-days

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONE hour prior to chemotherapy with food.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 22
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONE hour prior to chemotherapy with food.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 2
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 3
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 4
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 23
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 24
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 25
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONE hour prior to chemotherapy.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 22
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: ONE hour prior to chemotherapy.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 22
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: In 1000 mL of sodium chloride 0.9%, prior to cISplatin infusion.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 22
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: In 500 - 1000 mL of sodium chloride 0.9%, depending on stability. Ensure patient has passed urine as per institutional policy. Hypersensitivity risk increases with number of cycles of cISplatin.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: After cISplatin infusion. If cISplatin is infused in 1000 mL, centres may choose to omit this bag of fluid.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 22
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: After cISplatin infusion. If cISplatin is infused in 1000 mL, centres may choose to omit this bag of fluid.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: EIGHT hours after chemotherapy OR before bed.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 22
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: EIGHT hours after chemotherapy OR before bed.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: When required for nausea and/or vomiting. Warning: may cause drowsiness. Consider starting dose at 25 mg and increasing as tolerated/required. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. Note that domperidone is not recommended in combination with olanzapine and ondansetron due to potential risk of QT prolongation.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

PlanDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition
    l: CcaPlanDefinition
text:
  status:
    v: extensions
  div:
    v: Part 2: cARBOplatin and PACLItaxel (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel) Treatment Overview Commence within 3 weeks after completion of radiation therapy. This regimen follows cISplatin chemoradiation, not to be confused with GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only]. Cycles 1 to 4 - 21 days Cycle length: 21 Cycle details Cycles 1 to 4 - 21 days Medication Dose Route Days Max Duration dexamethasone * 20 mg oral administration 0 aprepitant 125 mg oral administration 1 aprepitant 80 mg oral administration 2, 3 dexamethasone * 12 mg oral administration 1 dexamethasone * 8 mg oral administration 2, 3 ondansetron 8 mg oral administration 1 loratadine * 10 mg oral administration 1 famotidine * 20 mg oral administration 1 PACLItaxel * 175 mg/m² intravenous 1 3 hours cARBOplatin * 5 AUC (area under the curve) intravenous 1 60 minutes ondansetron 8 mg oral administration 1 domperidone 10 mg Three times daily oral administration 1 Full details Cycles 1 to 4 - 21 days Day: 0 Medication Dose Route Max duration Details dexamethasone * 20 mg oral administration Instructions: Take the night prior to PACLItaxel infusion with food. If the initial infusion(s) of PACLItaxel are well tolerated, clinicians may decide at their discretion, to omit this dose. Day: 1 Medication Dose Route Max duration Details aprepitant 125 mg oral administration Instructions: ONE hour prior to chemotherapy. dexamethasone * 12 mg oral administration Instructions: ONE hour prior to chemotherapy with food. ondansetron 8 mg oral administration Instructions: ONE hour prior to chemotherapy. loratadine * 10 mg oral administration Instructions: ONE hour prior to PACLItaxel infusion. famotidine * 20 mg oral administration Instructions: ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. PACLItaxel * 175 mg/m² intravenous 3 hours Instructions: Prepare soluti…
contained: ActivityDefinition
  meta:
    profile:
      v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
      l: CcaActivityDefinition
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
      l: sact-off-label
    value: Boolean
      v: true
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
      l: sact-is-supportive-care
    value: Boolean
      v: true
  status:
    v: active
  product: CodeableConcept
    coding:
      system:
        v: http://nzmt.org.nz
        l: nzmt.org.nz
      code:
        v: 10238921000116102
      display:
        v: dexamethasone
    text:
      v: dexamethasone
  dosage:
    text:
      v: 20 mg by oral administration
    route:
      coding: http://snomed.info/id/386359008
      text:
        v: oral administration
    dose and rate:
      dose: Quantity
contained: ActivityDefinition
  meta:
    profile:
      v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
      l: CcaActivityDefinition
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
      l: sact-off-label
    value: Boolean
      v: false
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
      l: sact-is-supportive-care
    value: Boolean
      v: true
  status:
    v: active
  product: CodeableConcept
    coding:
      system:
        v: http://nzmt.org.nz
        l: nzmt.org.nz
      code:
        v: 10224481000116104
      display:
        v: aprepitant
    text:
      v: aprepitant
  dosage:
    text:
      v: 125 mg by oral administration
    route:
      coding: http://snomed.info/id/386359008
      text:
        v: oral administration
    dose and rate:
      dose: Quantity
contained: ActivityDefinition
  meta:
    profile:
      v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
      l: CcaActivityDefinition
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
      l: sact-off-label
    value: Boolean
      v: false
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
      l: sact-is-supportive-care
    value: Boolean
      v: true
  status:
    v: active
  product: CodeableConcept
    coding:
      system:
        v: http://nzmt.org.nz
        l: nzmt.org.nz
      code:
        v: 10224481000116104
      display:
        v: aprepitant
    text:
      v: aprepitant
  dosage:
    text:
      v: 80 mg by oral administration
    route:
      coding: http://snomed.info/id/386359008
      text:
        v: oral administration
    dose and rate:
      dose: Quantity
contained: ActivityDefinition
  meta:
    profile:
      v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
      l: CcaActivityDefinition
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
      l: sact-off-label
    value: Boolean
      v: true
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
      l: sact-is-supportive-care
    value: Boolean
      v: true
  status:
    v: active
  product: CodeableConcept
    coding:
      system:
        v: http://nzmt.org.nz
        l: nzmt.org.nz
      code:
        v: 10238921000116102
      display:
        v: dexamethasone
    text:
      v: dexamethasone
  dosage:
    text:
      v: 12 mg by oral administration
    route:
      coding: http://snomed.info/id/386359008
      text:
        v: oral administration
    dose and rate:
      dose: Quantity
contained: ActivityDefinition
  meta:
    profile:
      v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
      l: CcaActivityDefinition
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
      l: sact-off-label
    value: Boolean
      v: true
  extension:
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
      l: sact-is-supportive-care
    value: Boolean
      v: true
  status:
    v: active
  product: CodeableConcept
    coding:
      system:
        v: http://nzmt.org.nz
        l: nzmt.org.nz
      code:
        v: 10238921000116102
      display:
        v: dexamethasone
    text:
      v: dexamethasone
  dosage:
    text:
      v: 8 mg by oral administration
    route:
      coding: http://snomed.info/id/386359008
      text:
        v: oral administration

v: 386359008

v: 20

v: mg

v: 258684004

v: 386359008

v: 125

v: mg

v: 258684004

v: 386359008

v: 80

v: mg

v: 258684004

v: 386359008

v: 12

v: mg

v: 258684004

v: 386359008

dose: Quantity
  value:
    v: 8
  unit:
    v: mg
  system:
    v: http://snomed.info/sct
    l: sct
  code:
    v: 258684004

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: false
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10497011000116104
    display:
      v: ondansetron
  text:
    v: ondansetron
dosage:
  text:
    v: 8 mg by oral administration
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 8
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: true
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10056971000116105
    display:
      v: loratadine
  text:
    v: loratadine
dosage:
  text:
    v: 10 mg by oral administration
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 10
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: true
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10055201000116102
    display:
      v: famotidine
  text:
    v: famotidine
dosage:
  text:
    v: 20 mg by oral administration
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 20
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10050001000116101
    display:
      v: PACLItaxel
  text:
    v: PACLItaxel
dosage:
  text:
    v: 175 mg/m² over 3 hours by intravenous
  route:
    coding: http://snomed.info/id/386358000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386358000
    text:
      v: intravenous
  dose and rate:
    dose: Quantity
      value:
        v: 175
      unit:
        v: mg/m²
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 404216004
    rate: Range

v: 3

v: H

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10147121000116104
    display:
      v: cARBOplatin
  text:
    v: cARBOplatin
dosage:
  text:
    v: 5 AUC (area under the curve) over 60 minutes by intravenous
  route:
    coding: http://snomed.info/id/386358000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386358000
    text:
      v: intravenous
  dose and rate:
    dose: Quantity
      value:
        v: 5
      unit:
        v: AUC (area under the curve)
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 413573002
    rate: Range

v: 60

v: Min

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: false
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10497011000116104
    display:
      v: ondansetron
  text:
    v: ondansetron
dosage:
  text:
    v: 8 mg by oral administration
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 8
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

ActivityDefinition
meta:
  profile:
    v: http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition
    l: CcaActivityDefinition
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-off-label
    l: sact-off-label
  value: Boolean
    v: false
extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-is-supportive-care
    l: sact-is-supportive-care
  value: Boolean
    v: true
status:
  v: active
product: CodeableConcept
  coding:
    system:
      v: http://nzmt.org.nz
      l: nzmt.org.nz
    code:
      v: 10472211000116103
    display:
      v: domperidone
  text:
    v: domperidone
dosage:
  text:
    v: 10 mg Three times daily by oral administration
  timing:
    code:
      coding: http://snomed.info/id/229798009
      text:
        v: Three times daily
  route:
    coding: http://snomed.info/id/386359008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 386359008
    text:
      v: oral administration
  dose and rate:
    dose: Quantity
      value:
        v: 10
      unit:
        v: mg
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 258684004

v: 229798009

v: TID

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions
  l: sact-plan-instructions
value: Markdown
  v: Commence within 3 weeks after completion of radiation therapy. This regimen follows cISplatin chemoradiation, not to be confused with GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer
  l: sact-disclaimer
value: Markdown
  v: The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/419219000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 419219000
    text:
      v: Emetogenicity
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/75540009
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 75540009
    text:
      v: High
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/81286007
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 81286007
    text:
      v: Growth factor support
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/54371000210105
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 54371000210105
    text:
      v: Recommended for secondary prophylaxis
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/421961002
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 421961002
    text:
      v: Hypersensitivity / Infusion related reaction risk
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/723509005
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 723509005
    text:
      v: High - routine premedication recommended
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

system:
  v: CUSTOM
  l: CUSTOM

v: 0.0.4

v: GYN - cARBOplatin and PACLItaxel [following chemoradiation]

v: Part 2: cARBOplatin and PACLItaxel (GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel)

v: Gynaecological - cARBOplatin and PACLItaxel [following chemoradiation]

coding:
  system:
    v: http://terminology.hl7.org/CodeSystem/plan-definition-type
    l: plan-definition-type
  code:
    v: clinical-protocol

v: active

v: 2022-10-13

v: New Zealand Medicines Formulary LP

v: A drug treatment regimen for Gynaecological - cARBOplatin and PACLItaxel [following chemoradiation]

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/usage-context-type
    l: usage-context-type
  code:
    v: focus
value: CodeableConcept
  coding: http://snomed.info/id/310789003
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 310789003
  text:
    v: Gynaecological

v: All rights reserved.

name:
  v: New Zealand Medicines Formulary LP

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189
url:
  v: https://pubmed.ncbi.nlm.nih.gov/29449189
  l: https://pubmed.ncbi.nlm.nih.gov/29449189
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/29449189
    l: https://pubmed.ncbi.nlm.nih.gov/29449189

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040
url:
  v: https://pubmed.ncbi.nlm.nih.gov/27397040
  l: https://pubmed.ncbi.nlm.nih.gov/27397040
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/27397040
    l: https://pubmed.ncbi.nlm.nih.gov/27397040

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626
url:
  v: https://pubmed.ncbi.nlm.nih.gov/31345626
  l: https://pubmed.ncbi.nlm.nih.gov/31345626
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/31345626
    l: https://pubmed.ncbi.nlm.nih.gov/31345626

type:
  v: citation
display:
  v: Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641. , PMID: 25089112
url:
  v: https://pubmed.ncbi.nlm.nih.gov/25089112
  l: https://pubmed.ncbi.nlm.nih.gov/25089112
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/25089112
    l: https://pubmed.ncbi.nlm.nih.gov/25089112

type:
  v: citation
display:
  v: Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).

type:
  v: citation
display:
  v: Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020).

prefix:
  v: 1
description:
  v: Cycles 1 to 4 - 21 days
timing: Timing
  repeat:
    count:
      v: 4
    duration:
      v: 21
    duration unit:
      v: d
selection behavior:
  v: all
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 0
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: Take the night prior to PACLItaxel infusion with food. If the initial infusion(s) of PACLItaxel are well tolerated, clinicians may decide at their discretion, to omit this dose.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 2
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily in the morning.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 3
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily in the morning.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy with food.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 2
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 3
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONCE daily in the morning with food. Dose and duration may be individualised at clinician’s discretion.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to chemotherapy.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to PACLItaxel infusion.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
    url:
      v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
      l: sact-timing-of-days
  definition: Canonical
action:
  extension:
    extension:
      url:
        v: day
        l: day
      value: Integer
        v: 1
    extension:
      url:
        v: instructions
        l: instructions
      value: Markdown
        v: Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy.
  definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: Hypersensitivity risk increases with number of cycles of cARBOplatin.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: EIGHT hours after chemotherapy OR before bed.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

extension:
  extension:
    url:
      v: day
      l: day
    value: Integer
      v: 1
  extension:
    url:
      v: instructions
      l: instructions
    value: Markdown
      v: When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days
    l: sact-timing-of-days
definition: Canonical

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-treatment-setting
  l: sact-treatment-setting
value: CodeableConcept
  coding: http://snomed.info/id/373846009
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 373846009
  text:
    v: Adjuvant

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions
  l: sact-plan-instructions
value: Markdown
  v: This regimen consists of two parts: cISplatin chemoradiation followed by cARBOplatin and PACLItaxel. Do not confuse with the chemotherapy-only regimen: GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only].

url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer
  l: sact-disclaimer
value: Markdown
  v: The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/419219000
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 419219000
    text:
      v: Emetogenicity
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/75540009
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 75540009
    text:
      v: High
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/81286007
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 81286007
    text:
      v: Growth factor support
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/255372005
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 255372005
    text:
      v: Variable
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/281800008
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 281800008
    text:
      v: Hydration
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/255372005
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 255372005
    text:
      v: Variable
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

extension:
  url:
    v: factor
    l: factor
  value: CodeableConcept
    coding: http://snomed.info/id/421961002
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 421961002
    text:
      v: Hypersensitivity / Infusion related reaction risk
extension:
  url:
    v: value
    l: value
  value: CodeableConcept
    coding: http://snomed.info/id/255372005
      system:
        v: http://snomed.info/sct
        l: sct
      code:
        v: 255372005
    text:
      v: Variable
url:
  v: http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor
  l: sact-support-factor

system:
  v: http://snomed.info/sct
  l: sct
value:
  v: 60071000210106

v: 0.1.0

v: GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

v: GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

v: Gynaecological Endometrial Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

coding:
  system:
    v: http://terminology.hl7.org/CodeSystem/plan-definition-type
    l: plan-definition-type
  code:
    v: clinical-protocol

v: active

v: 2022-10-28

v: Te Aho o Te Kahu, Cancer Control Agency

v: A drug treatment regimen for Gynaecological Endometrial Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/usage-context-type
    l: usage-context-type
  code:
    v: focus
value: CodeableConcept
  coding: http://snomed.info/id/310789003
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 310789003
  text:
    v: Gynaecological

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/usage-context-type
    l: usage-context-type
  code:
    v: focus
value: CodeableConcept
  coding: http://snomed.info/id/93781006
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 93781006
  text:
    v: Endometrial

v: All rights reserved.

v: 2022-10-28

v: 2022-10-28

name:
  v: New Zealand Medicines Formulary LP

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2018. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 19(3):295-309., PMID: 29449189
url:
  v: https://pubmed.ncbi.nlm.nih.gov/29449189
  l: https://pubmed.ncbi.nlm.nih.gov/29449189
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/29449189
    l: https://pubmed.ncbi.nlm.nih.gov/29449189

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2016. "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial." Lancet Oncol 17(8):1114-1126., PMID: 27397040
url:
  v: https://pubmed.ncbi.nlm.nih.gov/27397040
  l: https://pubmed.ncbi.nlm.nih.gov/27397040
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/27397040
    l: https://pubmed.ncbi.nlm.nih.gov/27397040

type:
  v: citation
display:
  v: de Boer, S. M., M. E. Powell, L. Mileshkin, et al. 2019. "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial." Lancet Oncol 20(9):1273-1285., PMID: 31345626
url:
  v: https://pubmed.ncbi.nlm.nih.gov/31345626
  l: https://pubmed.ncbi.nlm.nih.gov/31345626
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/31345626
    l: https://pubmed.ncbi.nlm.nih.gov/31345626

type:
  v: citation
display:
  v: Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630-e641., PMID: 25089112
url:
  v: https://pubmed.ncbi.nlm.nih.gov/25089112
  l: https://pubmed.ncbi.nlm.nih.gov/25089112
document:
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/25089112
    l: https://pubmed.ncbi.nlm.nih.gov/25089112

type:
  v: citation
display:
  v: Castells, M.C., Matulonis, U.A., and Horton, TM. Infusion reactions to systemic chemotherapy. Savarese DMF and Feldweg AM, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy (Accessed 26 March 2021).

type:
  v: citation
display:
  v: Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020).

extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-child-regimen-extra-details
    l: sact-child-regimen-extra-details
  value: Markdown
    v: Commence within 4 to 6 weeks of surgery and in relation to radiation therapy as per institutional policy.
title:
  v: Part 1: cISplatin chemoradiation
selection behavior:
  v: all
definition: Canonical
  l: 6c16faca-cb95-4db6-ab7d-433b4d991532?version=10

extension:
  url:
    v: http://hl7.org.nz/fhir/StructureDefinition/sact-child-regimen-extra-details
    l: sact-child-regimen-extra-details
  value: Markdown
    v: Commence within 3 weeks after completion of radiation therapy.
title:
  v: Part 2: cARBOplatin and PACLItaxel
selection behavior:
  v: all
definition: Canonical
  l: 60f966e0-b24e-47fa-9e0c-d90abec4e58e?version=10